INFORS HT Opens New Offices in the USA
News Jan 06, 2014
On January 1st 2014, INFORS HT has opened new offices in the USA.
INFORS HT has, until now, been represented in the USA by ATR (Appropriate Technical Resources Inc.). From January 1st 2014, INFORS HT is going to take over this part of the ATR business - including its infrastructure, the existing customer relations, and full complement of staff.
In order to guarantee a seamless continuity of service to their customers, all sales and service offices as well as production teams will remain unchanged, as will any current contact personnel.
By increasing its presence in the USA, INFORS HT will not only expand its customer base but give its customers direct day-to-day contact with INFORS HT representatives and no longer via a third party.
Marcel Brauchli, CEO of INFORS HT, points out: “We’re proud of our new branches and look forward to having direct contact with our customers in the USA. We’re convinced that, in this way, we can improve customer relations and build more successful long term partnerships.”
This new direct contact will also bring about an added value to customers. They will have access to a committed team who have a wealth of experience, technical know-how and innovative thinking that is second-to-none.
The new CEO of Infors USA Inc., Simon Egli, holds a master degree in biotechnology engineering from the University of Waedenswil (CH).
Before joining INFORS HT at the headquarters in Switzerland, he worked in various bioprocess production and validation positions at a management level. He has been with INFORS HT for 3 years.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018